View clinical trials related to Severe Chronic Neutropenia.
Filter by:Purpose of the study is to investigate the safety, immunogenicity and the efficacy of Zarzio®/Filgrastim HEXAL® under chromic administration. Study was initiated as a post marketing authorization commitment to European Medicines Agency (EMA). Subsequent submission of long term safety and immunogenicity data from pooled studies and post-marketing experience have addressed the commitment and study no longer necessary to be continued and hence prematurely terminated. No patients were ongoing in the study at the time of study termination.
This is a multicenter Phase 2 randomized parallel-group study to determine the effect of Telintra treatment on severe chronic neutropenia. Patients will be randomized to Telintra or enter an observation period with an option to crossover to Telintra treatment in a 1:1 allocation.